ANN ARBOR – HandyLab will work closely with Nanogen on a new two-year, $10.4 million contract to develop a molecular diagnostic assay that can be used by the Center For Disease Control and Prevention to identify and respond to a flue pandemic.
The molecular diagnostic test will also be developed in partnership with the Medical College of Wisconsin. The test will be significantly more sensitive than current rapid flu tests and is expected to be conducted in less than half the time it takes to run current molecular tests.
The Nanogen proposal to the CDC included the use of Nanogen’s proprietary MGB probe technology for real-time PCR and anticipates the use of off-the-shelf instrumentation for sample handling and detection, including the HandyLab Raider system, a microfluidic real-time PCR technology, which will significantly shorten time to result.
�??Our collaboration with Nanogen on this project validates Raider’s performance for microfluidic real-time PCR technology�?� said Mark Powelson, HandyLab’s Vice President of Sales and Marketing, �??Our technology contribution to this project is anticipated to redefine the way respiratory testing is done.�?�
For more information, click on HandyLab.Com
a>>
